Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3599]

ASH 2014: Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase III trial

ASH 2014: Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase...

ASH 2014: Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

ASH 2014: Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

ASH 2014: T cell therapy leading to prolonged remission for children with aggressive leukaemia

ASH 2014: T cell therapy leading to prolonged remission for children with aggressive leukaemia

ASH 2014: Investigational antibody demonstrates efficacy and safety for aggressive multiple myeloma in phase I study

ASH 2014: Investigational antibody demonstrates efficacy and safety for aggressive multiple myeloma in phase I...

Scientists discover why patients respond to a melanoma drug

Scientists discover why patients respond to a melanoma drug

Five studies reveal insights into cancers responding to checkpoint blockade

Five studies reveal insights into cancers responding to checkpoint blockade

Vaccine targeting breast cancers produced robust immune response

Vaccine targeting breast cancers produced robust immune response

HIV drug blocks bone metastases in prostate cancer

HIV drug blocks bone metastases in prostate cancer

The leading oncology channel goes for gold

The leading oncology channel goes for gold

Study implicates TET1 enzyme as a master regulator in cancer

Study implicates TET1 enzyme as a master regulator in cancer

More from ecancer